ES2107375A1 - Liquid pharmaceutical formulations of ebastin by the oral route. - Google Patents

Liquid pharmaceutical formulations of ebastin by the oral route.

Info

Publication number
ES2107375A1
ES2107375A1 ES09501556A ES9501556A ES2107375A1 ES 2107375 A1 ES2107375 A1 ES 2107375A1 ES 09501556 A ES09501556 A ES 09501556A ES 9501556 A ES9501556 A ES 9501556A ES 2107375 A1 ES2107375 A1 ES 2107375A1
Authority
ES
Spain
Prior art keywords
ebastin
liquid pharmaceutical
pharmaceutical formulations
oral route
formulations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES09501556A
Other languages
Spanish (es)
Other versions
ES2107375B1 (en
Inventor
Jose Luis Fabregas
Mauri Jacinto Moraques
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Almirall SA
Original Assignee
Laboratorios Almirall SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratorios Almirall SA filed Critical Laboratorios Almirall SA
Priority to ES9501556A priority Critical patent/ES2107375B1/en
Publication of ES2107375A1 publication Critical patent/ES2107375A1/en
Application granted granted Critical
Publication of ES2107375B1 publication Critical patent/ES2107375B1/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Liquid pharmaceutical formulations of ebastin by the oral route. Liquid pharmaceutical formulations of 4-diphenylmethoxy-1- [3-(4-tert-butylbenzoyl)propyl]piperidine, the common name of which is ebastin, which contain hydroxylated carboxylic acids, non-ionic surfactants and medium-chain polyols in a proportion between 1:1:3:25 and 3:10:25:500, respectively, together with pharmaceutically acceptable excipients or diluents. These formulations are used for the treatment of allergic processes such as rhinitis, urticaria, dermatitis or conjunctivitis.
ES9501556A 1995-08-01 1995-08-01 LIQUID PHARMACEUTICAL FORMULATIONS OF EBASTIN BY ORAL WAY. Expired - Fee Related ES2107375B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
ES9501556A ES2107375B1 (en) 1995-08-01 1995-08-01 LIQUID PHARMACEUTICAL FORMULATIONS OF EBASTIN BY ORAL WAY.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES9501556A ES2107375B1 (en) 1995-08-01 1995-08-01 LIQUID PHARMACEUTICAL FORMULATIONS OF EBASTIN BY ORAL WAY.

Publications (2)

Publication Number Publication Date
ES2107375A1 true ES2107375A1 (en) 1997-11-16
ES2107375B1 ES2107375B1 (en) 1998-07-01

Family

ID=8291245

Family Applications (1)

Application Number Title Priority Date Filing Date
ES9501556A Expired - Fee Related ES2107375B1 (en) 1995-08-01 1995-08-01 LIQUID PHARMACEUTICAL FORMULATIONS OF EBASTIN BY ORAL WAY.

Country Status (1)

Country Link
ES (1) ES2107375B1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013081562A1 (en) 2011-10-13 2013-06-06 Mahmut Bilgic Oral formulations comprising ebastine

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0171331A1 (en) * 1984-08-03 1986-02-12 Laboratoire Vaillant Defresne Liquid composition containing quinine formate
FR2624736A1 (en) * 1987-12-16 1989-06-23 Dietlin Francois Novel water-dispersible pharmaceutical compositions based on ornidazole
WO1992016210A1 (en) * 1991-03-13 1992-10-01 Rhone-Poulenc Rorer S.A. Novel liquid compositions based on derivatives of 1,4 substituted piperidine
ES2052075T3 (en) * 1989-01-23 1994-07-01 Merrell Dow Pharma LIQUID PHARMACEUTICAL COMPOSITION FOR DERIVATIVES OF PIPERIDINOALCANOL.
US5574045A (en) * 1995-06-06 1996-11-12 Hoechst Marion Roussel, Inc. Oral pharmaceutical composition of piperidinoalkanol compounds in solution form

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0171331A1 (en) * 1984-08-03 1986-02-12 Laboratoire Vaillant Defresne Liquid composition containing quinine formate
FR2624736A1 (en) * 1987-12-16 1989-06-23 Dietlin Francois Novel water-dispersible pharmaceutical compositions based on ornidazole
ES2052075T3 (en) * 1989-01-23 1994-07-01 Merrell Dow Pharma LIQUID PHARMACEUTICAL COMPOSITION FOR DERIVATIVES OF PIPERIDINOALCANOL.
WO1992016210A1 (en) * 1991-03-13 1992-10-01 Rhone-Poulenc Rorer S.A. Novel liquid compositions based on derivatives of 1,4 substituted piperidine
US5574045A (en) * 1995-06-06 1996-11-12 Hoechst Marion Roussel, Inc. Oral pharmaceutical composition of piperidinoalkanol compounds in solution form

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013081562A1 (en) 2011-10-13 2013-06-06 Mahmut Bilgic Oral formulations comprising ebastine

Also Published As

Publication number Publication date
ES2107375B1 (en) 1998-07-01

Similar Documents

Publication Publication Date Title
MY103352A (en) Piperazinyl-heterocyclic compounds
PL361341A1 (en) Novel pharmaceutical composition
CA2260145A1 (en) Use of l-acetylcarnitine, l-isovalerylcarnitine, l-propionylcarnitine for increasing the levels of igf-1
ZA967746B (en) Treatment of tinnitus using neuroprotective agents.
NO903911D0 (en) PROCEDURE FOR THE PREPARATION OF 4-HYDROXYTETRAHYDROPYRAN-2-ON AND THE SIMILAR DIHYDROXYCARBOXYLIC ACID DERIVATIVES, SALTS AND ESTERS, THEIR USE AS MEDICINES, PHARMACEUTICAL PATTERIES AND PHARMACEUTICAL PATTERIES.
ES2052065T3 (en) DISPERSIBLE FORMULATION.
KR0148213B1 (en) Phenyla lkan(en)oic acid and pharmaceutical composition comprising the same
GB9310095D0 (en) Therapeutic compounds
IT1283225B1 (en) STRAINS OF BACTERIA, PHARMACEUTICAL COMPOSITION CONTAINING ONE OR MORE OF SUCH STRAINS AND USE OF THE SAME FOR THE PREVENTION AND THERAPY OF
NO973912L (en) Preventive or therapeutic drug for Alzheimer's disease
MY103210A (en) Arylpiperazinyl-alkylene-phenyl-heterocyclic compounds.
PT790236E (en) 5- (2- (4- (1,2-BENZISOYZAZOL-3-YL) -1-PYRAZAZYL) -ETHYL-6-CHLORO-1,3-DIHYDRO-2H-INDOL-2-ONA
CA2135709A1 (en) Melatonin derivatives for use in treating sleep disorders
PH31643A (en) 2-Oxidole-1-carboxamide pharmaceutical agents for the treatment of alzheimer's disease.
ES2107375A1 (en) Liquid pharmaceutical formulations of ebastin by the oral route.
PT1152762E (en) USE OF DEOXYGEGANIN IN THE TREATMENT OF ALZHEIMER'S DEMENTIA
EP0618812A4 (en) Use of protease nexin-i as an antiinflammatory.
DK0657431T3 (en) 4-Phenyl-3-substituted 1,4-dihydropyridine esters with cerebral action.
DK47988D0 (en) SUBSTITUTED 3-PHENYL-7H-THIAZOLOOE3,2-BAAOE1,2,4AATRIAZIN-7-ONER, THEIR PREPARATION AND APPLICATION AS MEDICINAL PRODUCTS, AND THE PRODUCTS USED INTERMEDIATELY
DE58902264D1 (en) BETA LACTAM ANTIBIOTICS, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS AND IN MEDICINAL PRODUCTS.
GR3018126T3 (en) 4-[(Thiophene-2-carbonyl)oxy]pyrrolidine-2-carboxylic acid, its preparation and its use as anti-inflammatory and anti-dystrophic agent.
IT9082655A0 (en) PERFECTED EQUIPMENT FOR THE TREATMENT OF VISUAL DEFECTS, PARTICULARLY FOR ANXIOMETROPIC AND STRABIBLE ANBLIOPIA AND SOME CORTICAL LESIONS.

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 19971116

Kind code of ref document: A1

Effective date: 19971116

PC2A Transfer of patent
FD2A Announcement of lapse in spain

Effective date: 20180806